Sutro Biopharma

Sutro Biopharma

STRO· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -37.1% in FY2025

Jane Chung, R.Ph. is the CEO of Sutro Biopharma and was paid $1.6M in FY2025 (Dec), up 9%.

Pay$100 in the stock at the end of FY22 → $14
CEO pay is from each Sutro Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1William J. NewellFY2025
  2. 2Jane Chung, R.Ph.FY2025
  3. 3Hans-Peter Gerber, Ph.D.FY2025
  4. 4Gregory ChowFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Sutro Biopharma paid its 4 named executives $5.0M in total in FY2025 (Dec). CEO Jane Chung, R.Ph. was paid $1.6M of that.

Name
William J. NewellFormer Chief Executive Officer
Jane Chung, R.Ph.Chief Executive Officer
Hans-Peter Gerber, Ph.D.Chief Scientific Officer
Gregory ChowChief Financial OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2025 (Dec) proxy of Sutro Biopharma names 18 peer companies for pay. Pay versus performance data of Sutro Biopharma for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Michael DybbsDirector · 7 yr on the boardIndependentScience and Technology—Paid as an executive
  • Jon WiggintonDirector · 5 yr on the boardIndependentCompensation, Science and Technology (Chair)—Paid as an executive
  • Heidi HunterDirector · 4 yr on the boardIndependentAudit, Science and Technology—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 22, 2026FY2025
Annual report10-KMar 23, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KMar 13, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KMar 25, 2024FY2023